Advertisement
UK markets open in 2 hours 28 minutes

  • NIKKEI 225

    37,106.59
    -973.11 (-2.56%)
     

  • HANG SENG

    16,184.02
    -201.85 (-1.23%)
     

  • CRUDE OIL

    84.70
    +1.97 (+2.38%)
     

  • GOLD FUTURES

    2,402.70
    +4.70 (+0.20%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,059.89
    +141.66 (+0.28%)
     

  • CMC Crypto 200

    1,286.23
    +400.69 (+44.00%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

GSK drug boosts response rates in blood cancer patients -study

Reuters - UK Focus

Aug 23 (Reuters) - British Drugmaker GlaxoSmithKline on Friday said its experimental cancer treatment belantamab mafodotin met the primary goal of a study for the treatment of patients with a type of blood cancer.

Two doses of the drug, also called GSK2857916, boosted response rates in adults who received prior treatment for multiple myeloma, a cancer that forms in white blood cells, GSK said, adding that it intends to submit data from the trial for regulatory filings. (Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham)